Tocilizumab Effect on Lipid Profile in Correlation to Cardiovascular Events: A Retrospective Cohort Study

Figure 2

Kaplan–Meier estimate of the time-to-variable lipid profile elevation. (a) The median survival time (high CHOL-free time) for the treatment group was 36 months and for the control group 60 months. The median survival time was significantly longer in the control than in the treatment group (log-rank test, , ). (b) The median survival time (high TRIG-free time) for the treatment group was 36 months and for the control group 55 months. The median survival time was not significantly different between the control and the treatment group (log-rank test, , ). (c) The median survival time (high LDL-free time) for the treatment group was 36 months and for the control group 60 months. The median survival time was significantly longer in the control than in the treatment group (log-rank test, , ). (d) The median survival time (high HDL-free time) for the treatment group was 18 months and for the control group 30 months. The median survival time was significantly longer in the control than in the treatment group (log-rank test, , ).

(a)

(b)

(c)

(d)